Mouse models of lipodystrophy: Key reagents for the understanding of the metabolic syndrome

Ingrid Wernstedt Asterholm, Nils Halberg, Philipp E. Scherer

Research output: Contribution to journalReview article

32 Scopus citations

Abstract

Both the disproportionate loss of adipose tissue in the case of lipodystrophies and the disproportionate gain of adipose tissue in obesity are frequently associated with an increase in insulin resistance and its complications. Leptin replacement is a very promising therapeutic approach for the management of the complications of lipodystrophy. By contrast, leptin treatment for the reversal of obesity-related metabolic disorders has not proven to be successful. There is a need to better understand both of these phenomena. Mouse models of lipodystrophy may provide us with new pharmaceutical targets for the treatment and prevention of metabolic disturbances related to dysfunctional adipose tissue both in the context of lipodystrophy and obesity.

Original languageEnglish (US)
Pages (from-to)17-24
Number of pages8
JournalDrug Discovery Today: Disease Models
Volume4
Issue number1
DOIs
StatePublished - Dec 28 2007

    Fingerprint

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this